Compliance With Parathyroid Hormone Analog Medications at a Single Osteoporosis Treatment Center.

Johnson AH, Brennan JC, Boudani D, Chapa L, Kidd G, Turcotte JJ, Morganti C

Cureus22 Apr 2025Cited by 2 (Europe PMC)

PMID40416275PMCIDPMC12098788DOI10.7759/cureus.82773PepBankPUB-40416275

Summary

Background Osteoporosis is the most common metabolic bone disease and is more common in female patients and the elderly. The costs associated with osteoporotic fractures present a significant burden on the healthcare system. While effective pharmacologic therapy exists, treatment initiation and compliance remain suboptimal, leading to increased morbidity. This study evaluated compliance with parathyroid hormone analogs and identified reasons for non-compliance. Methods This was a retrospective study of patients prescribed parathyroid hormone analogs from a single osteoporosis clinic from 2017 to 2022. Of the 100 patients included, 42 were prescribed teriparatide and 58 were prescribed abaloparatide. The primary outcomes of interest were continued compliance with medication therapy and reasons for non-compliance. The secondary outcome of interest was fracture rate. Univariate analyses were performed to identify differences between the two groups, and a Kaplan-Meier curve was generated to show overall compliance. Results The average treatment duration was 15.5 months (95% CI: 13.5-17.4 months); 54 (54%) patients completed the full 24-month medication course. Abaloparatide patients had higher rates of non-compliance than teriparatide patients (33 (56.9%) vs. 13 (31.0%); p=0.018) and had a significantly shorter time to non-compliance (4.1 ± 4.6 vs. 8.8 ± 6.4 months; p=0.027). There was a significant difference in reason for non-compliance between early (≤3 months) and late non-compliant patients (p=0.001). About 19 (79.2%) patients were non-compliant early because of side effects, while 10 (45.5%) patients were non-compliant late because of financial reasons. There were no differences in fracture rates between the two groups. Conclusion More than half of the patients in this study completed the full two-year course of treatment, and the average duration of treatment was over 15 months. The overall fracture rate during and after treatment was low. Financial concerns and side effects were the most common reasons for non-compliance. An additional study would be needed to evaluate methods for improving patient compliance with parathyroid hormone analogs.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyOther
In osteoporosis patients, abaloparatide was linked to higher non-compliance than teriparatide, 56.9% versus 31.0%.
In plain wordsIn osteoporosis patients, abaloparatide was linked to higher non-compliance than teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseNon-compliance rate
Study
n = 100
Comparator
teriparatide
Analysis
Primary
Outcome group
Treatment adherence and retention · Musculoskeletal
Studied dose
Dose not stated
Measurements
Non-compliance
56.9%
abaloparatide
Non-compliance
31%
teriparatide
Source sentences
Summary
Abaloparatide patients had higher rates of non-compliance than teriparatide patients (33 (56.9%) vs. 13 (31.0%); p=0.018) and had a significantly shorter time to non-compliance (4.1 ± 4.6 vs. 8.8 ± 6.4 months; p=0.027).
2 context sentences(design, population, supporting numbers)
Summary · context
Methods This was a retrospective study of patients prescribed parathyroid hormone analogs from a single osteoporosis clinic from 2017 to 2022.
Summary · context
Of the 100 patients included, 42 were prescribed teriparatide and 58 were prescribed abaloparatide.
Show in the study text Report a problemFND-4041627503
02HumanObservational studyOther
In osteoporosis patients, abaloparatide was linked to shorter time to non-compliance than teriparatide, 4.1 versus 8.8 months.
In plain wordsIn osteoporosis patients, abaloparatide was linked to earlier non-compliance than teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseTime to non-compliance
Study
n: not reported in source
Comparator
teriparatide
Analysis
Primary
Outcome group
Treatment adherence and retention · Musculoskeletal
Studied dose
Dose not stated
Measurements
Time to non-compliance
4.1 months
abaloparatide
Time to non-compliance
8.8 months
teriparatide
Source sentences
Summary
Abaloparatide patients had higher rates of non-compliance than teriparatide patients (33 (56.9%) vs. 13 (31.0%); p=0.018) and had a significantly shorter time to non-compliance (4.1 ± 4.6 vs. 8.8 ± 6.4 months; p=0.027).
2 context sentences(design, population, supporting numbers)
Summary · context
Methods This was a retrospective study of patients prescribed parathyroid hormone analogs from a single osteoporosis clinic from 2017 to 2022.
Summary · context
Of the 100 patients included, 42 were prescribed teriparatide and 58 were prescribed abaloparatide.
Show in the study text Report a problemFND-4041627504
03HumanObservational studyEfficacy outcome
In osteoporosis patients, fracture rates did not differ between abaloparatide and teriparatide groups.
In plain wordsIn osteoporosis patients, fracture rates did not differ between abaloparatide and teriparatide groups.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeFracture rate
Study
n = 100
Comparator
teriparatide
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
There were no differences in fracture rates between the two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Methods This was a retrospective study of patients prescribed parathyroid hormone analogs from a single osteoporosis clinic from 2017 to 2022.
Summary · context
Of the 100 patients included, 42 were prescribed teriparatide and 58 were prescribed abaloparatide.
Show in the study text Report a problemFND-4041627508

Studies that did not test the peptide alone5

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

04HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
In osteoporosis patients, pooled teriparatide and abaloparatide treatment duration averaged 15.5 months.
In plain wordsIn osteoporosis patients, treatment with pooled teriparatide and abaloparatide averaged 15.5 months.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableTreatment duration
Study
n = 100
Analysis
Primary
Outcome group
Treatment adherence and retention · Musculoskeletal
Measurements
Treatment duration
15.5 months
pooled PTH analogs
Source sentences
Summary
Results The average treatment duration was 15.5 months (95% CI: 13.5-17.4 months); 54 (54%) patients completed the full 24-month medication course.
2 context sentences(design, population, supporting numbers)
Summary · context
Methods This was a retrospective study of patients prescribed parathyroid hormone analogs from a single osteoporosis clinic from 2017 to 2022.
Summary · context
Of the 100 patients included, 42 were prescribed teriparatide and 58 were prescribed abaloparatide.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-4041627501
05HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
In osteoporosis patients, 54% completed the full 24-month course of pooled teriparatide or abaloparatide treatment.
In plain wordsIn osteoporosis patients, 54% completed the full 24-month course of pooled teriparatide or abaloparatide treatment.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableFull course completion
Study
n = 100
Analysis
Primary
Outcome group
Treatment adherence and retention · Musculoskeletal
Measurements
Completion
54%
pooled PTH analogs
Source sentences
Summary
Results The average treatment duration was 15.5 months (95% CI: 13.5-17.4 months); 54 (54%) patients completed the full 24-month medication course.
2 context sentences(design, population, supporting numbers)
Summary · context
Methods This was a retrospective study of patients prescribed parathyroid hormone analogs from a single osteoporosis clinic from 2017 to 2022.
Summary · context
Of the 100 patients included, 42 were prescribed teriparatide and 58 were prescribed abaloparatide.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-4041627502
06HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
In osteoporosis patients receiving pooled PTH analogs, reasons for non-compliance differed between early and late non-compliance.
In plain wordsIn osteoporosis patients receiving pooled PTH analogs, reasons for non-compliance differed between early and late non-compliance.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableReasons for non-compliance by timing
Study
n: not reported in source
Comparator
late non-compliance
Analysis
Primary
Outcome group
Treatment adherence and retention · Musculoskeletal
Source sentences
Summary
There was a significant difference in reason for non-compliance between early (≤3 months) and late non-compliant patients (p=0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Methods This was a retrospective study of patients prescribed parathyroid hormone analogs from a single osteoporosis clinic from 2017 to 2022.
Summary · context
Of the 100 patients included, 42 were prescribed teriparatide and 58 were prescribed abaloparatide.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-4041627505
07HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
In osteoporosis patients receiving pooled PTH analogs, side effects explained early non-compliance in 19 patients, or 79.2%.
In plain wordsIn osteoporosis patients receiving pooled PTH analogs, side effects explained early non-compliance in 19 patients.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableEarly non-compliance because of side effects
Study
n: not reported in source
Analysis
Primary
Outcome group
Treatment adherence and retention · Musculoskeletal
Measurements
Side-effect-related early non-compliance
79.2%
early non-compliant patients
Source sentences
Summary
About 19 (79.2%) patients were non-compliant early because of side effects, while 10 (45.5%) patients were non-compliant late because of financial reasons.
2 context sentences(design, population, supporting numbers)
Summary · context
Methods This was a retrospective study of patients prescribed parathyroid hormone analogs from a single osteoporosis clinic from 2017 to 2022.
Summary · context
Of the 100 patients included, 42 were prescribed teriparatide and 58 were prescribed abaloparatide.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-4041627506
08HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
In osteoporosis patients receiving pooled PTH analogs, financial reasons explained late non-compliance in 10 patients, or 45.5%.
In plain wordsIn osteoporosis patients receiving pooled PTH analogs, financial reasons explained late non-compliance in 10 patients.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableLate non-compliance because of financial reasons
Study
n: not reported in source
Analysis
Primary
Outcome group
Treatment adherence and retention · Musculoskeletal
Measurements
Financial late non-compliance
45.5%
late non-compliant patients
Source sentences
Summary
About 19 (79.2%) patients were non-compliant early because of side effects, while 10 (45.5%) patients were non-compliant late because of financial reasons.
2 context sentences(design, population, supporting numbers)
Summary · context
Methods This was a retrospective study of patients prescribed parathyroid hormone analogs from a single osteoporosis clinic from 2017 to 2022.
Summary · context
Of the 100 patients included, 42 were prescribed teriparatide and 58 were prescribed abaloparatide.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-4041627507

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.